Dipping in 2020
30/12/19 -"We have re-worked our financial model after some initial adjustments. Our general view on the company remains broadly unchanged, but the incorporation of the AR's full set of figures and a stronger ..."
Pages
68
Language
English
Published on
30/12/19
You may also be interested by these reports :
14/07/26
Dräger delivered a strong set of Q2 2026 preliminary figures, with both revenue and earnings ahead of consensus. The guidance upgrade on the EBIT ...
10/07/26
Following Thermo Fisher’s unsuccessful bid in 2020, Qiagen gradually restructured its business, focusing on non-COVID growth avenues. However, in ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...